Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

News Conference News EAS 2023

Variable Response to Novel PCSK9 Inhibitor Lerodalcibep in LIBERATE-HoFH

Michael O'Riordan

May 24, 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

News Conference News EAS 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Michael O'Riordan

May 23, 2023

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

News Conference News ACC 2022

Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70

Michael O'Riordan

April 07, 2022

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.